A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
406 patients around the world
Available in Argentina
Karuna Therapeutics
406Patients around the world
This study is for people with
Alzheimer disease
Requirements for the patient
To 90 Years
All Gender
Medical requirements
Patients who are 55 to 90 years of age, inclusive, at the time of Screening (Visit 1).
Patients who are diagnosed with possible AD or probable AD.
Patient must have a magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain taken during or subsequent to the onset of dementia to rule out other central nervous system (CNS) disease that could account for the dementia syndrome.
Patient must have a history of psychotic symptoms for at least 2 months prior to Screening (Visit 1).
Psychotic symptoms that are primarily attributable to a condition other than the AD causing the dementia.
History of major depressive episode with psychotic features during the 12 months prior to Screening, or history of bipolar disorder, schizophrenia, or schizoaffective disorder.
Patients are not able to participate if they have certain safety concerns, including certain laboratory test irregularities.
